| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2004;44:602.)
© 2004 American Heart Association, Inc.
Brief Reviews |
From the Division of Clinical and Administrative Pharmacy (J.L.M., B.L.C., G.A.), College of Pharmacy, University of Iowa, and the Department of Family Medicine (B.L.C., P.A.J., G.A.), Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City.
Correspondence to Barry L. Carter, PharmD, Professor and Head, Division of Clinical and Administrative Pharmacy, College of Pharmacy, Department of Family Medicine, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, IA 52242. E-mail barry-carter{at}uiowa.edu
| Abstract |
|---|
|
|
|---|
Key Words: hypertension, detection and control population lifestyle epidemiology
| Introduction |
|---|
|
|
|---|
Although the National Heart, Lung, and Blood Institute (NHLBI) has published 7 guidelines for the treatment of hypertension,814 control of high blood pressure remains suboptimal. An estimated 40% of the 50 million persons in the United States with hypertension remain untreated, and 66% of hypertensive patients have blood pressure values that are not controlled to the recommended levels.14,15 Many studies have concluded that physician adherence to hypertension guidelines has been low.1622 It is tempting, therefore, to connect poor blood pressure control to poor adherence to hypertension guidelines.
However, valid and meaningful conclusions regarding physician adherence and its link to blood pressure control rest on the completion of 2 tasks. First, physician adherence to hypertension guidelines must be assessed accurately. Second, the relation between physician adherence and blood pressure control must be empirically demonstrated.
This article reviews pertinent literature regarding physician adherence to hypertension guidelines and the relation of adherence to blood pressure outcomes. The review focuses on methods that limit evaluation of adherence and concludes with recommendations for strengthening future adherence research.
| Literature Search |
|---|
|
|
|---|
| Measuring Adherence to Clinical Practice Guidelines for Hypertension |
|---|
|
|
|---|
| Studies That Used Prescription Data to Evaluate Guideline Adherence |
|---|
|
|
|---|
|
The authors of these prescription and dispensing studies have drawn differing conclusions regarding guideline adherence. Monane et al16 Siegel and Lopez,17 and Siegel et al34 concluded that physicians were not adherent to guideline recommendations. Nelson and Knapp,36 focusing on the most frequently prescribed antihypertensive drug classes, concluded that prescribing patterns were generally consistent with guideline recommendations. However, the trends that they described can be interpreted as not being consistent with guideline recommendations.38 Campbell et al37 concluded that their reported trends reflected adherence to the Canadian Hypertension Society (CHS) guidelines and attributed the improvement in practice to an extensive educational intervention aimed at improving hypertension management. Study conclusions become unclear and perhaps inconsistent when studies do not explicitly define what constitutes adherence. Prescription studies, therefore, point out the need to explicitly define criteria against which guideline adherence can be measured.
Another weakness of these prescription and dispensing studies is their failure to describe the effect of comorbid conditions on prescriptive practice. None of these studies was able to evaluate the number of prescriptions written or dispensed for subpopulations of patients with specific comorbidities. Siegel et al34 speculated that analysis of subpopulations would be unlikely to affect overall results, but they did not present any data to substantiate their position. Siegel and Lopez17 commented that ACEIs were prescribed at a greater rate than would be warranted for the subpopulation of patients with congestive heart failure (CHF) and that the infrequent and decreasing use of ß-blockers did not parallel the widespread presence of coronary artery disease (CAD). Campbell and colleagues37 noted that the observed increases in ACEI and ß-blocker prescriptions were more substantial than the changes in nitrate and digoxin prescriptions (used as markers of CAD and CHF), suggesting that these comorbid conditions alone were not the primary reason for the increased prescribing rates.
However, some degree of evidence suggests that the degree of physician adherence might vary, depending on the presence of a comorbid condition. Carter et al,28 for example, found that although CCB use increased from 1996 to 1998 (P<0.02), patients with diabetes or heart failure were more likely to be taking the recommended ACEIs or diuretics, whereas patients with CAD were most often treated with the recommended ACEIs, CCBs, diuretics, or ß-blockers. Adherence to recommended therapies, therefore, appeared to be improved for patient subpopulations with diabetes, heart failure, or CAD. Weiss et al29 found varying adherence to recommended treatments for patients with comorbid conditions. The majority of patients with diabetes were prescribed recommended ACEIs as initial monotherapy between 1997 and 2000, and as recommended, no patients with CHF or diabetes were treated with CCBs. However, a smaller percentage of patients with CHF were treated initially with ACEIs or ß-blockers. Finally, Clause and Hamilton18 found that only 40% of patients prescribed a CCB or an ACEI during 1994, 1997, and 1999 had a compelling indication for 1 of these agents as recognized by JNC V or VI, indicating that prescriptive trends cannot be explained solely by parallel trends in the presence of comorbid conditions. These conflicting findings, at a minimum, underscore the importance of evaluating prescriptive practices for subpopulations with specific comorbidities. Because physicians frequently prescribe antihypertensives on the basis of patient age, race, and coexisting disease,30 consideration of comorbidities is critical to an accurate evaluation of adherence.
Several additional weaknesses plague prescription and dispensing studies. First, they assume that prescribing trends and pharmacy databases are good surrogate markers of adherence to guidelines. However, this has never been shown. Second, they fail to describe other important aspects of hypertension care, including diagnosis, evaluation, and follow-up, thereby limiting conclusions regarding adherence. Finally, JNC pharmacological recommendations have changed over time, from stepped care to the use of a range of agents based on individualized indications to the more recent focus on use of diuretics. These changing recommendations complicate and potentially confound studies of adherence that are based on pharmacological trends.
| Studies That Used Survey Data to Evaluate Guideline Adherence |
|---|
|
|
|---|
However, other survey studies have concluded that practice was less adherent. Hyman and Pavlik35 found that 52% percent of physicians would not start treatment for middle-aged adults with a systolic blood pressure between 140 and 160 mm Hg, only 24% would start treatment for elderly patients with a systolic pressure of <160 mm Hg, and physicians most frequently chose ACEIs for monotherapy. The physicians surveyed by Mehta et al19 reported several areas of practice that were not consistent with JNC V, including the initiation of appropriate antihypertensive treatment for patients with comorbidities, patients >75 years of age, blacks, or those with mild renal failure. Overall adherence to the British Hypertension Society guidelines was found to be low when Dickerson et al20 examined blood pressure measurement, nonpharmacological treatment, threshold for intervention, treatment of the elderly, isolated systolic hypertension, treatment goals, drug use and dosage, laboratory monitoring, and follow-up.
Patient survey data have paralleled physician survey data. A study by Xu et al40 that assessed adherence to JNC V guidelines found that diuretics and ß-blockers were used in 36.72% of patients, whereas CCBs and ACEIs were used in 67.49%. The authors concluded that compliance to JNC guidelines was low and that increasing compliance might reduce the costs of prescriptions and other medical services. Henderson et al32 concluded that overall treatment of black and Latino respondents did not correspond closely to JNC VI, based on the high rates of ACEI and CCB use and low ß-blocker use.
It is critical to note that physician and patient surveys provide a qualified view of adherence because they rely on self-reported data. Disparities can exist between actual performance and reports of performance.41,42 Consequently, survey data, taken alone, might not lead to valid conclusions regarding adherence.
| Studies That Used Medical Record Data as a Measure of Hypertension Care |
|---|
|
|
|---|
In contrast, Cuspidi et al,22 using 12 explicit criteria to evaluate physician adherence to the 1999 World Health Organization/International Society of Hypertension Guidelines, found poor adherence to the minimum recommended clinical and laboratory evaluation work-up, high use of ACEIs (65.6%), lower use of diuretics (49.1%), and poor patient outcomes, with only 18.7% of patients having a controlled blood pressure. The retrospective chart review by McAlister et al43 of 969 patients similarly found several areas of practice that were not adherent to the CHS guidelines: high use of ACEIs and CCBs, lower use of diuretics and ß-blockers, low recommendations for lifestyle modifications, and wide variation in the performance of laboratory tests.
Asch et al21 used 13 explicit criteria supported by JNC guidelines or randomized controlled trials to measure adherence to hypertension quality indicators in 234 female patients. Medical records were abstracted for blood pressure measurement, medications, and visit frequency. Subjects were evaluated for physician adherence to only those criteria for which they were eligible (mean=3). Adherence to individual criteria ranged from 0% to 100%. Total adherence rates were suboptimal, with the average woman receiving 64% of the recommended care for which she was eligible. When adherence rates were ranked, none of the women whose blood pressure was controlled (
140/90 mm Hg) received care ranked in the lowest tertile, suggesting that better care was positively associated with blood pressure control. Several aspects of the Asch study are notable: quality indicators were based on either guideline recommendations or clinical trials, the indicators spanned various aspects of hypertension management, and the study related guideline adherence to blood pressure outcomes. However, the only comorbidity addressed was diabetes. Furthermore, the study did not evaluate the degree to which instances of nonadherence might have been justified, possibly resulting in a more negative conclusion than might have been warranted.
Berlowitz and colleagues44 reviewed medical records of 800 hypertensive men at Veterans Administration hospitals, assessed predictors of physician decisions to change antihypertensive medication, and evaluated the association between intensity of treatment and blood pressure control. Physicians frequently failed to increase or change medications when blood pressures were elevated, doing so for only 25.6% of cases where there were elevations in both systolic (
155 mm Hg) and diastolic (
90 mm Hg) pressures and for only 21.6% of cases where only systolic pressure was elevated (
165 mm Hg). The investigators did find a significant association between more intensive therapy and improved blood pressure control, even after adjustment for baseline characteristics (P<0.01). Furthermore, a high percentage of patients (59.6%) whose blood pressure was
160/90 mm Hg at the outcome visit had antihypertensive regimens that were ranked in the lowest quintile of intensity. Unfortunately, this study does not address questions related to physician adherence to hypertension guidelines. However, the studys examination of the relation between treatment intensity and blood pressure control makes an important contribution to the literature by commenting on physicians lack of aggressiveness in achieving systolic blood pressure targets.
Adherence studies that use medical record data critically assume that documentation in medical records accurately reflects practice. Although this assumption is reasonable, the adequacy of physician documentation could vary across physicians and across studies. Indeed, the differing conclusions in these studies might reflect variation in the adequacy of physician documentation as well as actual variation in adherence. Because none of the studies that were reviewed demonstrated a close relation between documentation and practice, their conclusions regarding adherence remain tentative.
| Conclusions |
|---|
|
|
|---|
|
Investigators who are evaluating physician adherence to hypertension guidelines can use several strategies to strengthen future research. First, the limits imposed by the type of data used to measure adherence must be considered and when possible, minimized. Survey self-report data should not be used as a sole measure of adherence, because its validity is difficult to determine. Prescription data should not be used as a sole measure of adherence, because it cannot capture the wide range of physician practices that comprise hypertension care. Ideally, several physician practices should be examined, including assessment, treatment, achievement of blood pressure goals, follow-up, and monitoring. Second, researchers will need to define and validate explicit criteria for measuring adherence, thus enabling researchers to compare adherence across studies and provide clinicians with a taxonomy for describing areas where practice is weak. Use of measurable criteria that reflect the spectrum of care delivery provides the foundation for a comprehensive measure of guideline adherence.24,45,46 Third, incorporating an implicit review, as well as an explicit review, permits researchers to consider factors that reflect justifiable nonadherence to a guideline. Implicit review recognizes physicians needs to consider unique patient characteristics and situations. Finally, linking process measures to blood pressure outcomes makes studies of adherence clinically meaningful.
Perspectives
This evaluation of the literature reveals many limitations in our ability to make inferences about adherence to hypertension guidelines. An ongoing study is testing a comprehensive set of explicit criteria for measuring adherence to hypertension guidelines and combining this explicit measurement with an implicit review process.47 Agreed-on methods and criteria for evaluating adherence could serve as an evidence-based algorithm against which clinicians could evaluate their practice. Researchers, in turn, could use these methods to test strategies for improving adherence when it is found to be weak. Developing a consensus on appropriate methods for evaluating adherence, therefore, will constitute a critical step in advancing improvements in the quality of hypertension care.
| Acknowledgments |
|---|
Received June 4, 2004; first decision June 25, 2004; accepted August 26, 2004.
| References |
|---|
|
|
|---|
2. Wagner EH. Chronic disease management: what will it take to improve care for chronic illness? Eff Clin Pract. 1998; 1: 24.[Medline] [Order article via Infotrieve]
3. Lomas J, Anderson GM, Domnick-Pierre K, Vayda E, Enkin MW, Hannah WJ. Do practice guidelines guide practice? the effect of a consensus statement on the practice of physicians. N Engl J Med. 1989; 321: 13061311.[Abstract]
4. Worrall G, Chaulk P, Freake D. The effects of clinical practice guidelines on patient outcomes in primary care: a systematic review. Can Med Assoc J. 1997; 156: 17051712.[Abstract]
5. Hayward RS. Clinical practice guidelines on trial. Can Med Assoc J. 1997; 156: 17251727.[Medline] [Order article via Infotrieve]
6. Gupta L, Ward JE, Hayward RS. Clinical practice guidelines in general practice: a national survey of recall, attitudes and impact. Med J Aust. 1997; 166: 6972.[Medline] [Order article via Infotrieve]
7. Woolf SH. Practice guidelines: a new reality in medicine, III: impact on patient care. Arch Intern Med. 1993; 153: 26462655.
8. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 1977; 237: 255261.
9. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The 1980 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1980; 140: 12801285.
10. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The 1984 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1984; 144: 10451057.
11. 1988 Joint National Committee. The 1988 report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1988; 148: 10231038.
12. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). Arch Intern Med. 1993; 153: 154183.
13. Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997; 157: 24132446.
14. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42: 12061252.
15. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 19882000. JAMA. 2003; 290: 199206.
16. Monane M, Glynn RJ, Gurwitz JH, Bohn RL, Levin R, Avorn J. Trends in medication choices for hypertension in the elderly: the decline of the thiazides. Hypertension. 1995; 25: 10451051.
17. Siegel D, Lopez J. Trends in antihypertensive drug use in the United States: do the JNC V recommendations affect prescribing? Fifth Joint National Commission on the Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 1997; 278: 17451748.
18. Clause SL, Hamilton RA. Medicaid prescriber compliance with Joint National Committee VI hypertension treatment guidelines. Ann Pharmacother. 2002; 36: 15051511.[Abstract]
19. Mehta SS, Wilcox CS, Schulman KA. Treatment of hypertension in patients with comorbidities: results from the study of hypertensive prescribing practices (SHyPP). Am J Hypertens. 1999; 12: 333340.[Medline] [Order article via Infotrieve]
20. Dickerson JE, Garratt CJ, Brown MJ. Management of hypertension in general practice: agreements with and variations from the British Hypertension Society guidelines. J Hum Hypertens. 1995; 9: 835839.[Medline] [Order article via Infotrieve]
21. Asch SM, Kerr EA, Lapuerta P, Law A, McGlynn EA. A new approach for measuring quality of care for women with hypertension. Arch Intern Med. 2001; 161: 13291335.
22. Cuspidi C, Michev I, Lonati L, Vaccarella A, Cristofari M, Garavelli G, Palumbo G, Meani S, Leonetti G, Magrini F, Zanchetti A. Compliance to hypertension guidelines in clinical practice: a multicentre pilot study in Italy. J Hum Hypertens. 2002; 16: 699703.[CrossRef][Medline] [Order article via Infotrieve]
23. Lawler FH, Viviani N. Patient and physician perspectives regarding treatment of diabetes: compliance with practice guidelines. J Fam Pract. 1997; 44: 369373.[Medline] [Order article via Infotrieve]
24. Schuster MA, Asch SM, McGlynn EA, Kerr EA, Hardy AM, Gifford DS. Development of a quality of care measurement system for children and adolescents: methodological considerations and comparisons with a system for adult women. Arch Pediatr Adolesc Med. 1997; 151: 10851092.
25. Worrall G, Freake D, Kelland J, Pickle A, Keenan T. Care of patients with type II diabetes: a study of family physicians compliance with clinical practice guidelines. J Fam Pract. 1997; 44: 374381.[Medline] [Order article via Infotrieve]
26. Malone DC, Shaban HM. Adherence to ATS guidelines for hospitalized patients with community-acquired pneumonia. Ann Pharmacother. 2001; 35: 11801185.[Abstract]
27. Naiman DJ, Barker LR. Adherence to the JNC VI guidelines for the treatment of hypertension in the resident clinic. Md Med J. 1999; 48: 307311.[Medline] [Order article via Infotrieve]
28. Carter BL, Malone DC, Ellis SL, Dombrowski RC. Antihypertensive drug utilization in hypertensive veterans with complex medication profiles. J Clin Hypertens. 2000; 2: 172180.
29. Weiss R, Buckley K, Clifford T. Changing patterns of initial drug therapy for the treatment of hypertension in a Medicaid population, 19972000. Clin Ther. 2002; 24: 14511462.[Medline] [Order article via Infotrieve]
30. Carter BL, Kriesel HT, Steinkraus L, Knudson R. Antihypertensive drug-prescribing patterns of internists and family physicians. J Fam Pract. 1989; 29: 257261.[Medline] [Order article via Infotrieve]
31. Cloher TP, Whelton PK. Physician approach to the recognition and initial management of hypertension: results of a statewide survey of Maryland physicians. Arch Intern Med. 1986; 146: 529533.
32. Henderson SO, Bretsky P, DeQuattro V, Henderson BE. Treatment of hypertension in African Americans and Latinos: the effect of JNC VI on urban prescribing practices. J Clin Hypertens. 2003; 5: 107112.
33. Manolio TA, Cutler JA, Furberg CD, Psaty BM, Whelton PK, Applegate WB. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med. 1995; 155: 829837.
34. Siegel D, Lopez J, Meier J, Cunningham F. Changes in the pharmacologic treatment of hypertension in the Department of Veterans Affairs 19971999: decreased use of calcium antagonists and increased use of ß-blockers and thiazide diuretics. Am J Hypertens. 2001; 14: 957962.[CrossRef][Medline] [Order article via Infotrieve]
35. Hyman DJ, Pavlik VN. Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. Arch Intern Med. 2000; 160: 22812286.
36. Nelson CR, Knapp DA. Trends in antihypertensive drug therapy of ambulatory patients by US office-based physicians. Hypertension. 2000; 36: 600603.
37. Campbell NR, McAlister FA, Brant R, Levine M, Drouin D, Feldman R, Herman R, Zarnke K. Temporal trends in antihypertensive drug prescriptions in Canada before and after introduction of the Canadian Hypertension Education Program. J Hypertens. 2003; 21: 15911597.[CrossRef][Medline] [Order article via Infotrieve]
38. Balas EA. Trends in antihypertensive drug therapy by US office-based physicians. Hypertension. 2001; 37: E12.[Medline] [Order article via Infotrieve]
39. McAlister FA, Teo KK, Laupacis A. A survey of management practices for isolated systolic hypertension. J Am Geriatr Soc. 1997; 45: 12191222.[Medline] [Order article via Infotrieve]
40. Xu KT, Moloney M, Phillips S. Economics of suboptimal drug use: cost-savings of using JNC-recommended medications for management of uncomplicated essential hypertension. Am J Manag Care. 2003; 9: 529536.[Medline] [Order article via Infotrieve]
41. Eccles M, Ford GA, Duggan S, Steen N. Are postal questionnaire surveys of reported activity valid? an exploration using general practitioner management of hypertension in older people. Br J Gen Pract. 1999; 49: 3538.[Medline] [Order article via Infotrieve]
42. Montano DE, Phillips WR. Cancer screening by primary care physicians: a comparison of rates obtained from physician self-report, patient survey, and chart audit. Am J Public Health. 1995; 85: 795800.
43. McAlister FA, Teo KK, Lewanczuk RZ, Wells G, Montague TJ. Contemporary practice patterns in the management of newly diagnosed hypertension. Can Med Assoc J. 1997; 157: 2330.[Abstract]
44. Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B, Moskowitz MA. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998; 339: 19571963.
45. Olson KK, Autio LA. Measuring quality of care for essential hypertension. Holist Nurs Pract. 2001; 15: 2234.[Medline] [Order article via Infotrieve]
46. James PA, Cowan TM, Graham RP, Jaen CR, Majeroni BA, Schwartz JS. Heart failure in primary care: measuring the quality of care. J Fam Pract. 1999; 48: 790798.[Medline] [Order article via Infotrieve]
47. Milchak JL, Carter BL, Bakris GL, Black HR, Jones DW, Zillich AJ. Selection of explicit criteria for a JNC-7 adherence tool. Am J Hypertens. 2004; 15: 144A. Abstract.
This article has been cited by other articles:
![]() |
B. L. Carter, G. Ardery, J. D. Dawson, P. A. James, G. R. Bergus, W. R. Doucette, E. A. Chrischilles, C. L. Franciscus, and Y. Xu Physician and Pharmacist Collaboration to Improve Blood Pressure Control Arch Intern Med, November 23, 2009; 169(21): 1996 - 2002. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. L. Carter Antihypertensive Prescribing: Do We Have Reason to Celebrate? Hypertension, November 1, 2006; 48(5): 816 - 817. [Full Text] [PDF] |
||||
![]() |
J. Onysko, C. Maxwell, M. Eliasziw, J. X. Zhang, H. Johansen, N. R.C. Campbell, and for the Canadian Hypertension Education Program Large Increases in Hypertension Diagnosis and Treatment in Canada After a Healthcare Professional Education Program Hypertension, November 1, 2006; 48(5): 853 - 860. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. R.C. Campbell, K. Tu, R. Brant, M. Duong-Hua, F. A. McAlister, and for the Canadian Hypertension Education Program Ou The Impact of the Canadian Hypertension Education Program on Antihypertensive Prescribing Trends Hypertension, January 1, 2006; 47(1): 22 - 28. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. J. Wang and R. S. Vasan Epidemiology of Uncontrolled Hypertension in the United States Circulation, September 13, 2005; 112(11): 1651 - 1662. [Full Text] [PDF] |
||||
![]() |
K. Tu, N. R.C. Campbell, M. Duong-Hua, and F. A. McAlister Hypertension Management in the Elderly Has Improved: Ontario Prescribing Trends, 1994 to 2002 Hypertension, June 1, 2005; 45(6): 1113 - 1118. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |